These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35523595)

  • 21. Use of
    Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
    J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline
    Martínez A; Infante JR; Quirós J; Rayo JI; Serrano J; Moreno M; Jiménez P; Cobo A; Baena A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(3):164-170. PubMed ID: 34452867
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.
    Yoo J; Choi JY; Moon SH; Bae DS; Park SB; Choe YS; Lee KH; Kim BT
    Int J Gynecol Cancer; 2012 Sep; 22(7):1226-33. PubMed ID: 22810970
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
    BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
    Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
    Cong L; Wang S; Gao T; Hu L
    Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer.
    Makino T; Yamasaki M; Tanaka K; Tatsumi M; Takiguchi S; Hatazawa J; Mori M; Doki Y
    Surgery; 2017 Oct; 162(4):836-845. PubMed ID: 28711321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
    Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
    J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.
    Lemarignier C; Di Fiore F; Marre C; Hapdey S; Modzelewski R; Gouel P; Michel P; Dubray B; Vera P
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2008-16. PubMed ID: 25037871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic value of the metabolically active tumour volume].
    Paumier A; Marquis A; Trémolières P; Lacombe M; Capitain O; Septans AL; Peyraga G; Gustin P; Vénara A; Ménager É; Visvikis D; Couturier O; Rio E; Hatt M
    Cancer Radiother; 2016 Feb; 20(1):24-9. PubMed ID: 26762703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
    Li Y; Zschaeck S; Lin Q; Chen S; Chen L; Wu H
    Radiat Oncol; 2019 Feb; 14(1):35. PubMed ID: 30782182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential values of metabolic tumor volume and heterogeneity measured with ¹⁸F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy.
    Liu Q; Fu XL; Yu W; Zhu ZF; Zhang YJ
    Nucl Med Commun; 2015 May; 36(5):423-9. PubMed ID: 25603275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma.
    Lee SJ; Choi JY; Lee HJ; Baek CH; Son YI; Hyun SH; Moon SH; Kim BT
    Korean J Radiol; 2012; 13(6):752-9. PubMed ID: 23118574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
    Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma.
    Makino T; Miyata H; Yamasaki M; Fujiwara Y; Takiguchi S; Nakajima K; Higuchi I; Hatazawa J; Mori M; Doki Y
    Surgery; 2010 Nov; 148(5):908-18. PubMed ID: 20378140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.